- $145.73m
- $119.82m
- $44.86m
- 41
- 18
- 52
- 30
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.25 | ||
| Price to Tang. Book | 6.25 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -43.58% | ||
| Return on Equity | -154.69% | ||
| Operating Margin | -41.87% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 14.11 | 16.48 | 22.16 | 30.93 | 44.85 | 61.15 | 85.1 | 32.91% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Augmedix, Inc. helps clinicians and patients form a human connection at the point of care. The Company uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. It also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patient’s health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.
Directors
- Manny Krakaris PRE
- Ian Shakil FDR
- Paul Ginocchio CFO
- Sandra Breber COO
- Saurav Chatterjee CTO
- Joseph Marks DRC
- Margie Traylor DRC
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 27th, 2018
- Public Since
- March 4th, 2021
- No. of Shareholders
- 3,820
- No. of Employees
- 1,430
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
NASDAQ Capital Market- Shares in Issue
- 48,739,739
- Address
- 111 Sutter Street, Suite 1300, SAN FRANCISCO, 94104
- Web
- https://augmedix.com/
- Phone
- +1 5619892208
- Contact
- Matt Chesler
- Auditors
- Grant Thornton LLP
Upcoming Events for AUGX
Similar to AUGX
Aeries Technology
NASDAQ Capital Market
ATIF Holdings
NASDAQ Capital Market
Baiya International
NASDAQ Capital Market
Bffi
NASDAQ Capital Market
BTCS
NASDAQ Capital Market
FAQ
As of Today at 19:03 UTC, shares in Augmedix are trading at $2.99. This share price information is delayed by 15 minutes.
Shares in Augmedix last closed at $2.99 and the price had moved by -12.06% over the past 365 days. In terms of relative price strength the Augmedix share price has underperformed the S&P500 Index by -26.82% over the past year.
The overall consensus recommendation for Augmedix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Augmedix does not currently pay a dividend.
Augmedix does not currently pay a dividend.
Augmedix does not currently pay a dividend.
To buy shares in Augmedix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.99, shares in Augmedix had a market capitalisation of $145.73m.
Here are the trading details for Augmedix:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AUGX
Based on an overall assessment of its quality, value and momentum Augmedix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Augmedix is $6.07. That is 103.01% above the last closing price of $2.99.
Analysts covering Augmedix currently have a consensus Earnings Per Share (EPS) forecast of -$0.51 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Augmedix. Over the past six months, its share price has underperformed the S&P500 Index by -50.32%.
As of the last closing price of $2.99, shares in Augmedix were trading -36.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Augmedix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Augmedix's management team is headed by:
- Manny Krakaris - PRE
- Ian Shakil - FDR
- Paul Ginocchio - CFO
- Sandra Breber - COO
- Saurav Chatterjee - CTO
- Joseph Marks - DRC
- Margie Traylor - DRC